Shots:

• Baxter will be the exclusive distributor of bioMérieux’s NEPHROCLEAR CCL14 test in the EU and the US following regulatory approval and launch in both territories. The companies will share in-country commercialization- while bioMérieux will retain control over the regulatory process
• The collaboration will add the diagnostic test to Baxter’s Acute Therapies portfolio- offering the tool to clinicians for managing the complexities of AKI. The agreement follows the agreement of the countries signed in 2019 to improve identification and treatment of AKI
• The company highlights the role CCL14 biomarkers in predicting persistent AKI in the RUBY study demonstrating that 33% met the criteria for persistent stage 3 AKI. The NEPHROCLEAR CCL14 test is not currently approved for use in the US & EU

­ Ref: Baxter | Image: MedGadget